Prognosticating survival of pineal parenchymal tumors of intermediate differentiation (PPTID) by grade
- PMID: 34606044
- DOI: 10.1007/s11060-021-03863-y
Prognosticating survival of pineal parenchymal tumors of intermediate differentiation (PPTID) by grade
Abstract
Background: Pineal parenchymal tumors of intermediate differentiation (PPTID) are a rare group of pineal parenchymal tumors classified by histology as either World Health Organization (WHO) Grades 2 or 3. The rarity of these tumors in adults has left a number of clinical management questions open. Correspondingly, the aim of this study was to aggregate a large PPTID cohort with sufficient statistical power from a large national cancer database to analyze prognostic parameters.
Methods: All PPTID patients aged over 18 years in the U.S. National Cancer Database (NCDB) between 2005 and 2016 were retrospectively reviewed. Data were summarized and survival was modeled using Kaplan-Meier and Cox regression analyses.
Results: A total of 103 adult PPTID patients were identified in the NCDB with 63 (61%) WHO Grade 2 and 40 (39%) WHO Grade 3 tumors. Overall, mean age was 53 ± 18 years with even gender distribution. A total of 75 (73%) patients underwent surgical resection for diagnosis, with gross total resection (GTR) was the most common resection outcome in 50/75 (67%). Chemotherapy was utilized in 18 (17%) patients, and radiation therapy in 37 (36%) patients. Overall, 5-year survival rate was estimated to be 54% (95% CI 42-64%), with mean survival was 84 (95% CI 69-99) months. Patients with Grade 2 tumors survived statistically longer than Grade 3 tumor counterparts (P < 0.01). Overall, older age (HR 1.09, P < 0.01) was associated with shorter survival, whereas GTR (HR 0.43, P = 0.02) was associated with longer survival. Both these parameters were significant within Grade 2 and Grade 3 subgroup analyses as well.
Conclusions: PPTID are rare tumors with expected mean survival more than 5 years, although Grade 2 tumors are expected to survive longer than Grade 3 tumors. Age and gross total resection are significant independent predictors of survival in PPTID overall, as well as within Grade 2 and Grade 3 subgroups separately. The prognostic role and benefit of adjuvant therapy is yet to be elucidated, mandating more molecular and biologic research be done to further optimize clinical management in the future.
Keywords: Database; Grade 2; Grade 3; NCDB; PPTID; Pineal parenchymal tumors of intermediate differentiation; Survival.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Clinicopathologic study of pineal parenchymal tumors of intermediate differentiation.World Neurosurg. 2014 May-Jun;81(5-6):783-9. doi: 10.1016/j.wneu.2013.02.007. Epub 2013 Feb 8. World Neurosurg. 2014. PMID: 23396072
-
Malignant Pineal Parenchymal Tumors in Adults: A National Cancer Database Analysis.Neurosurgery. 2022 Jun 1;90(6):807-815. doi: 10.1227/neu.0000000000001915. Epub 2022 Mar 23. Neurosurgery. 2022. PMID: 35311743
-
Histopathologic review of pineal parenchymal tumors identifies novel morphologic subtypes and prognostic factors for outcome.Neuro Oncol. 2017 Jan;19(1):78-88. doi: 10.1093/neuonc/now105. Epub 2016 Jun 9. Neuro Oncol. 2017. PMID: 27282397 Free PMC article.
-
Clinical experience and outcomes in patients with pineal parenchymal tumor of intermediate differentiation (PPTID): a single-institution analysis.J Neurooncol. 2022 Nov;160(2):527-534. doi: 10.1007/s11060-022-04174-6. Epub 2022 Oct 27. J Neurooncol. 2022. PMID: 36301435 Review.
-
Pineal Parenchymal Tumor of Intermediate Differentiation (PPTID) and Papillary Tumor of Pineal Region (PTPR): A Review.Neurol India. 2021 Sep-Oct;69(5):1153-1164. doi: 10.4103/0028-3886.329550. Neurol India. 2021. PMID: 34747779 Review.
Cited by
-
Understanding and Managing Pineal Parenchymal Tumors of Intermediate Differentiation: An In-Depth Exploration from Pathology to Adjuvant Therapies.J Clin Med. 2024 Feb 23;13(5):1266. doi: 10.3390/jcm13051266. J Clin Med. 2024. PMID: 38592098 Free PMC article. Review.
-
Pineal parenchymal tumor of intermediate differentiation: Case series and literature review: Is it time for a consensus?Surg Neurol Int. 2025 Apr 18;16:138. doi: 10.25259/SNI_1068_2024. eCollection 2025. Surg Neurol Int. 2025. PMID: 40353160 Free PMC article.
-
Survival and Malignant Transformation of Pineal Parenchymal Tumors: A 30-Year Retrospective Analysis in a Single-Institution.Brain Tumor Res Treat. 2023 Oct;11(4):254-265. doi: 10.14791/btrt.2023.0033. Brain Tumor Res Treat. 2023. PMID: 37953449 Free PMC article.
-
Diagnosis and Treatment of Pineal Region Tumors in Adults: A EURACAN Overview.Cancers (Basel). 2022 Jul 27;14(15):3646. doi: 10.3390/cancers14153646. Cancers (Basel). 2022. PMID: 35954310 Free PMC article. Review.
-
Clinicopathologic analysis of pineal parenchymal tumors of intermediate differentiation: a multi-institutional cohort study by the Kyushu Neuro-Oncology Study Group.J Neurooncol. 2023 Apr;162(2):425-433. doi: 10.1007/s11060-023-04310-w. Epub 2023 Apr 13. J Neurooncol. 2023. PMID: 37052748
References
-
- Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS (2020) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017. Neuro Oncol 22(12 Suppl 2):iv1–iv96. https://doi.org/10.1093/neuonc/noaa200 - DOI - PubMed - PMC
-
- Amato-Watkins AC, Lammie A, Hayhurst C, Leach P (2016) Pineal parenchymal tumours of intermediate differentiation - An evidence-based review of a new pathological entity. Br J Neurosurg 30(1):11–15. https://doi.org/10.3109/02688697.2015.1096912 - DOI - PubMed
-
- Smith AB, Rushing EJ, Smirniotopoulos JG (2010) From the archives of the AFIP: lesions of the pineal region: radiologic-pathologic correlation. Radiographics 30(7):2001–2020. https://doi.org/10.1148/rg.307105131 - DOI - PubMed
-
- Jouvet A, Saint-Pierre G, Fauchon F, Privat K, Bouffet E, Ruchoux MM, Chauveinc L, Fèvre-Montange M (2000) Pineal parenchymal tumors: a correlation of histological features with prognosis in 66 cases. Brain Pathol 10(1):49–60. https://doi.org/10.1111/j.1750-3639.2000.tb00242.x - DOI - PubMed
-
- Raleigh DR, Solomon DA, Lloyd SA, Lazar A, Garcia MA, Sneed PK, Clarke JL, McDermott MW, Berger MS, Tihan T, Haas-Kogan DA (2017) Histopathologic review of pineal parenchymal tumors identifies novel morphologic subtypes and prognostic factors for outcome. Neuro Oncol 19(1):78–88. https://doi.org/10.1093/neuonc/now105 - DOI - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical